Get the Stockscreener App
97.95
1.20%
-1.1256
Biontech Se Adr stock is traded at $97.95, with a volume of 318.34K.
It is down -1.20% in the last 24 hours and down -4.10% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$99.08
Open:
$98.43
24h Volume:
318.34K
Relative Volume:
0.28
Market Cap:
$24.59B
Revenue:
$3.26B
Net Income/Loss:
$-1.45B
P/E Ratio:
-16.68
EPS:
-5.871
Net Cash Flow:
$1.18B
1W Performance:
-2.95%
1M Performance:
-4.10%
6M Performance:
+14.26%
1Y Performance:
-0.21%
1-Day Range:
$97.60
$99.79
1-Week Range:
$96.64
$101.31
52-Week Range:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
97.91 | 24.75B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
524.46 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
199.35 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
747.08 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
960.38 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
201.19 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-16-26 | Upgrade | Goldman | Neutral → Buy |
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
BNTX Stock Quote Price and Forecast - CNN
BioNTech SE (BNTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioNTech SE (BNTX) stock price, news, quote and history - Yahoo Finance Australia
Form 4 BioNTech SE For: 25 September - Investing.com India
BioNTech (BNTX) 10K Form and Latest SEC Filings 2026 - MarketBeat
BNTX Stock Price and Chart — NASDAQ:BNTX - tradingview.com
BioNTech SE (22UA.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
eBay Upgraded, Airbnb Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction - Kalkine Media
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19 - ACCESS Newswire
BioNTech's lung cancer drug outperforms chemo in clinical study - mugglehead.com
BioNTech's Oncology Credibility Test Comes Down to Four Days in Seoul () - aktiencheck.de
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - morningstar.com
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):